Beta-3 adrenergic receptor agonists to treat pulmonary hypertension
Pulmonary hypertension (PH), defined as the increase of mean pulmonary blood pressure above normal values, encompasses a series of disorders characterized by the increase of pulmonary vascular resistance and progressive deterioration of the right ventricle. The incidence of pulmonary hypertension in the population is high and it is associated with high morbidity and mortality. Approximately two thirds of patients with left ventricular dysfunction (systolic or isolated diastolic) develop pulmonary hypertension. Currently, there is a lack of treatments for pulmonary hypertension.
CNIC and CLINIC researchers have described a novel effective treatment for pulmonary hypertension of different etiology, both chronic and acute. They have found that selective stimulation of beta-3 adrenergic receptors has a beneficial effect in pulmonary hypertension.
Scientific article: https://doi.org/10.1002/ejhf.2745NumberEP2891490B1, US10532038B2Priority date29/08/2012ApplicantsCNIC, CLINICInventorsBorja Ibáñez Cabeza, Valentín Fuster Carulla, Ana García-Álvarez